These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 37443486)
21. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer. Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X Front Immunol; 2023; 14():1126902. PubMed ID: 36891298 [TBL] [Abstract][Full Text] [Related]
22. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer. Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z Front Immunol; 2022; 13():951455. PubMed ID: 36189298 [TBL] [Abstract][Full Text] [Related]
23. Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients. Shen J; Zhang W; Jin Q; Gong F; Zhang H; Xu H; Li J; Yao H; Jiang X; Yang Y; Hong L; Mei J; Song Y; Zhou S Oncol Res; 2023; 32(2):339-351. PubMed ID: 38186570 [TBL] [Abstract][Full Text] [Related]
24. A four-gene signature in the tumor microenvironment that significantly associates with the prognosis of patients with breast cancer. Wang J; Yang Z; Zhang C; Ouyang J; Zhang G; Wu C Gene; 2020 Nov; 761():145049. PubMed ID: 32791092 [TBL] [Abstract][Full Text] [Related]
25. Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer. Chen F; Yang J; Fang M; Wu Y; Su D; Sheng Y J Clin Lab Anal; 2022 Apr; 36(4):e24302. PubMed ID: 35229919 [TBL] [Abstract][Full Text] [Related]
26. Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer. Li C; Zheng L; Xu G; Yuan Q; Di Z; Yang Y; Dong X; Hou J; Wu G Front Endocrinol (Lausanne); 2023; 14():1154741. PubMed ID: 37538794 [TBL] [Abstract][Full Text] [Related]
27. Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation. Li L; Yang W; Jia D; Zheng S; Gao Y; Wang G Breast Cancer; 2023 Jul; 30(4):666-684. PubMed ID: 37178414 [TBL] [Abstract][Full Text] [Related]
28. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. Zhou L; Fang H; Guo F; Yin M; Long H; Weng G J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868 [TBL] [Abstract][Full Text] [Related]
29. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma. Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q Front Immunol; 2021; 12():693062. PubMed ID: 34497605 [TBL] [Abstract][Full Text] [Related]
30. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma. Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J Front Immunol; 2022; 13():881359. PubMed ID: 35911752 [TBL] [Abstract][Full Text] [Related]
31. Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction. Sun Y; Yang M; Zhang Q Ann Transl Med; 2022 Dec; 10(24):1379. PubMed ID: 36660642 [TBL] [Abstract][Full Text] [Related]
32. A senescence-related lncRNA signature predicts prognosis and reflects immune landscape in HNSCC. Chen L; Lin J; Wen Y; Lan B; Xiong J; Fu Y; Chen Y; Chen CB Oral Oncol; 2024 Feb; 149():106659. PubMed ID: 38134702 [TBL] [Abstract][Full Text] [Related]
33. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer. Liu Y; He X; Yang YI J Biosci; 2024; 49():. PubMed ID: 38287674 [TBL] [Abstract][Full Text] [Related]
34. A glycolysis-related signature to improve the current treatment and prognostic evaluation for breast cancer. Feng S; Ning L; Zhang H; Wang Z; Lu Y PeerJ; 2024; 12():e17861. PubMed ID: 39119106 [TBL] [Abstract][Full Text] [Related]
35. A seven-nuclear receptor-based prognostic signature in breast cancer. Wu F; Chen W; Kang X; Jin L; Bai J; Zhang H; Zhang X Clin Transl Oncol; 2021 Jul; 23(7):1292-1303. PubMed ID: 33210236 [TBL] [Abstract][Full Text] [Related]
36. Bioinformatic analysis and experimental validation of six cuproptosis-associated genes as a prognostic signature of breast cancer. Chen X; Sun H; Yang C; Wang W; Lyu W; Zou K; Zhang F; Dai Z; He X; Dong H PeerJ; 2024; 12():e17419. PubMed ID: 38912044 [TBL] [Abstract][Full Text] [Related]
37. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma. Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774 [TBL] [Abstract][Full Text] [Related]
38. A new 4-gene-based prognostic model accurately predicts breast cancer prognosis and immunotherapy response by integrating WGCNA and bioinformatics analysis. Chen W; Kang Y; Sheng W; Huang Q; Cheng J; Pei S; Meng Y Front Immunol; 2024; 15():1331841. PubMed ID: 38370403 [TBL] [Abstract][Full Text] [Related]
39. Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy. Hong K; Cen K; Chen Q; Dai Y; Mai Y; Guo Y Front Immunol; 2023; 14():1128390. PubMed ID: 36761753 [TBL] [Abstract][Full Text] [Related]
40. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma. Zeng C; Yu H; Liu X; Liu Q; Jin J Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]